Open AccessCPX‐351 (Vyxeos ® ) can cause severe rash in acute myeloid leukemia—A case report
Author(s) -
Urbantat Ruth M.,
Popper Valentin,
Menschel Elisabeth,
Pfeilstöcker Michael,
Forjan Ernst,
Nader Alexander,
Sieghart Catherine R.,
Keil Felix,
Koller Elisabeth
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3909
Subject(s) - medicine , rash , myeloid leukemia , leukemia , dermatology , immunology
CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.